Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.68 |
| ▸ | ESR1 | P03372 | 6/20 | 0.60 |
| ▸ | ESR2 | Q92731 | 6/20 | 0.60 |
| ▸ | ESRRB | O95718 | 3/20 | 0.60 |
| ▸ | ESRRA | P11474 | 3/20 | 0.60 |
| ▸ | MAPT | P10636 | 3/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | GLA | P06280 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | TTR | P02766 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9073054 | 0.85 | MAPT (0.56) | LMNAESR1ESR2ESRRBESRRA | |
| Bromide SCHEMBL9069438 | 0.84 | MAPT (0.54) | LMNAESR1ESR2ESRRBESRRA | |
| SCHEMBL7692119 | 0.81 | ESR1 (0.64) | LMNAESR1ESR2ESRRBESRRA | |
| SCHEMBL3648083 | 0.81 | LMNA (0.72) | LMNAMAPTALDH1A1L3MBTL1POLB | |
| SCHEMBL30572382 | 0.81 | LMNA (1.00) | LMNAMAPTKDM4EALDH1A1L3MBTL1 | |
| SCHEMBL12247506 | 0.81 | KDM4E (0.57) | LMNAESR1ESR2ESRRBESRRA | |
| SCHEMBL10824124 | 0.81 | LMNA (0.72) | LMNAESR1ESR2ESRRBESRRA | |
| SCHEMBL4768081 | 0.81 | LMNA (1.00) | LMNAMAPTKDM4EALDH1A1L3MBTL1 | |
| SCHEMBL10518542 | 0.79 | LMNA (0.70) | LMNAESR1ESR2ESRRBESRRA | |
| Hydrochloric Acid SCHEMBL9494656 | 0.79 | LMNA (0.96) | LMNAMAPTKDM4EALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090023773-A1 | COMPOSITIONS AND METHODS FOR MODULATING GATED ION CHANNELS | PAINCEPTOR PHARMA CORPORATION (CA) | 2009-01-22 | — | — | US | disclosed |
| US-20090023773-A1 | COMPOSITIONS AND METHODS FOR MODULATING GATED ION CHANNELS | PAINCEPTOR PHARMA CORPORATION (CA) | 2009-01-22 | — | — | US | disclosed |
| US-20090023773-A1 | COMPOSITIONS AND METHODS FOR MODULATING GATED ION CHANNELS | PAINCEPTOR PHARMA CORPORATION (CA) | 2009-01-22 | — | — | US | disclosed |
| WO-2009000085-A1 | QUINOLINE AND QUINAZOLINE DERIVATIVES USEFUL AS MODULATORS OF GATED ION CHANNELS | PAINCEPTOR PHARMA CORPORATION (CA) | 2008-12-31 | — | — | WO | disclosed |
| WO-2009000085-A1 | QUINOLINE AND QUINAZOLINE DERIVATIVES USEFUL AS MODULATORS OF GATED ION CHANNELS | PAINCEPTOR PHARMA CORPORATION (CA) | 2008-12-31 | — | — | WO | disclosed |
| US-5506235-A | Quinoline derivatives as immunostimulants | PFIZER INC. (US) | 1996-04-09 | — | — | US | disclosed |
| EP-0597003-A1 | QUINOLINE DERIVATIVES AS IMMUNOSTIMULANTS | PFIZER INC. (US) | 1994-05-18 | — | — | EP | disclosed |
| WO-1993003030-A1 | QUINOLINE DERIVATIVES AS IMMUNOSTIMULANTS | PFIZER INC. (US) | 1993-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023773-A1 | COMPOSITIONS AND METHODS FOR MODULATING GATED ION CHANNELS | TRPV1, TRPV2, TRPA1 | LMNA 2848/4885ESR1 3278/4885ESR2 1461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.